top of page

Precision Medicines Against
LIpid-MEdiated Targets

Arrow Down

Lime Therapeutics is the lipids company.

We are a fast-growing biotechnology company focused on making a difference for patients. We are using our breakthrough LipidSense™ platform to hunt for novel targets and create new drugs that modulate aberrant lipid metabolism in many forms of cancer, cardiometabolic diseases, lysosomal storage diseases, and neurodegenerative disorders.

Intro
Leadership

Leadership

Team

Scientific and Chemistry Advisory Board

vanderheiden.jpg
schwartz.jpg

Robert Schwartz, MD, PhD

Weill Cornell Medicine

Matthew
Vander Heiden, MD, PhD

Massachusetts Institute of Technology (MIT)

perera.jpg

Rushika Perera, PhD

University of California,
San Francisco

tammela.jpg

Tuomas Tammela, MD, PhD

Memorial Sloan Kettering Cancer Center

jiang.jpg

Xuejun Jiang, PhD

Memorial Sloan Kettering Cancer Center

Francis Tavares Profile Picture xhghi_450x308.jpg

Francis Tavares, PhD

ChemoGenics BioPharma

Business Advisors

Robin Mansukhani Profile Picture.jpeg

Robin Mansukhani

CEO, Deciduous Therapeutics

jeff_hatfield.jpeg

Jeff Hatfield, MBA

Chairman of the Board of Directors, Vividion Therapeutics and ROME Therapeutics

Team
SAB
Biz Advisors
Technology

Technology

Creating Lipid-Altering Therapeutics

lipidsense-outlined.png

Lipid dysfunction is a hallmark of a broad range of diseases such as cancer, metabolic diseases, lysosomal storage diseases, and neurodegenerative disorders. Despite this, efforts to hunt for lipid-mediated targets and create novel therapies have remained elusive due to lack of technology. 

 

We've changed the game with the invention of an ultrasensitive lipid detection technology. LipidSense is a high-throughput screening platform that monitors lysosomal lipid flux in real time in live cells, in a high-throughput screening format, and in live animals. 

 

We can tell within seconds whether a particular therapy changes lipid flux. We are utilizing this platform to discover drugs that can alter cancer's access to lipids or restore lysosomal lipid function in metabolic diseases and neurodegenerative disorders.

Ultimately, we are exploring therapeutic opportunities to touch the lives of 100 million patients.

Publications

A Carbon Nanotube Optical Reporter Maps Endolysosomal Lipid Flux.  

Prakrit V. Jena, Daniel Roxbury, et. al.  

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5707631/

An optical nanoreporter of endolysosomal lipid accumulation reveals enduring effects of diet on hepatic macrophages in vivo.  

Thomas V. Galassi, Prakrit V. Jena, et. al.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6543545/

Long-term in vivo biocompatibility of single-walled carbon nanotubes

Thomas V. Galassi, et. al., and Daniel Heller

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7202660/

Our Supporters

Thank you to those supporting our efforts to develop life-changing therapeutics (partial list):

64c762a3e16b1dd0185ac88d_ZAKA logo_new.png
XSeed logo (2)_edited.png
XSeed logo (2)_edited.png
Bristol_Myers_Squibb-removebg-preview.png
Zuna-Color-removebg-preview.png
BFF_2018logo_BLACK-copy_0.png
EFL-Logo.png
Picture1.png
Case_Western_Reserve_University_seal.svg-removebg.png

Case Western Reserve University

Alumni Venture Fund

Allston-Venture-Fund-wText.png
LGB_edited.png
Little Green Bamboo

Invest together. Grow together.

Biolabs_atNYUL_highres.png
logo-no-background.png
HBS.png
Startup-Legal-Garage.png

Kent Johnson, MBA

Former CFO, BioLegend

Inaki Berenguer, PhD, MBA

Life Extension Ventures

Our Supporters

Careers

Please check back here for any openings

Careers
Contact

Contact

Headquarters

BioLabs@NYULangone

180 Varick St., Floor 6

New York, NY 10014

Inquiries

For any inquiries, please fill out the following form.

Thank you for submitting your message!

Inquiries
bottom of page